Edgestream Partners L.P. Boosts Stake in Humana Inc. (NYSE:HUM)

Edgestream Partners L.P. increased its holdings in Humana Inc. (NYSE:HUM - Free Report) by 372.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,515 shares of the insurance provider's stock after buying an additional 10,652 shares during the quarter. Edgestream Partners L.P.'s holdings in Humana were worth $3,429,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Ashton Thomas Securities LLC purchased a new stake in Humana in the 3rd quarter worth approximately $31,000. FPC Investment Advisory Inc. purchased a new stake in shares of Humana in the fourth quarter worth $27,000. Centricity Wealth Management LLC bought a new stake in shares of Humana during the 4th quarter valued at $30,000. Atwood & Palmer Inc. lifted its stake in shares of Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after buying an additional 60 shares in the last quarter. Finally, LRI Investments LLC lifted its stake in shares of Humana by 1,021.4% during the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider's stock valued at $50,000 after buying an additional 143 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Performance

Shares of Humana stock traded down $0.88 on Wednesday, reaching $249.32. 1,150,843 shares of the stock were exchanged, compared to its average volume of 1,660,458. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The business has a 50 day moving average price of $271.67 and a two-hundred day moving average price of $281.65. The firm has a market capitalization of $30.08 billion, a price-to-earnings ratio of 25.06, a PEG ratio of 2.05 and a beta of 0.57.

Remove Ads

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.42%. Humana's payout ratio is 35.58%.

Insider Buying and Selling

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the company's stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.32% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

HUM has been the topic of a number of recent analyst reports. Piper Sandler raised their price target on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a report on Wednesday, January 15th. Truist Financial boosted their price target on Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a report on Monday, January 6th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $283.00 price objective on shares of Humana in a report on Wednesday, February 12th. Morgan Stanley lowered their target price on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 12th. Finally, StockNews.com downgraded shares of Humana from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th. Twenty equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.